Posted by Michael Wonder on 29 Sep 2023
Karuna Therapeutics submits new drug application to US FDA for KarXT for the treatment of schizophrenia
28 September 2023 - KarXT, a dual M1/M4 muscarinic agonist, represents the first new mechanism of action to treat schizophrenia in several decades, if approved.
Karuna Therapeutics today announced the submission of a new drug application to the US FDA for KarXT (xanomeline-trospium) for the treatment of schizophrenia.
